glp-1 weight loss long-term Rx Trends: Real-World Data on GLP-1s for The Real Reason GLP-1 Weight

Some pharmaceutical companies offer savings programs or discount cards that can significantly reduce the out-of-pocket expenses, making the treatment more accessible for those who qualify

Caroline Messer, an endocrinologist at Northwell Lenox Hill Hospital, told The Post, of working with patients to get to the root cause of their obesity or weight gain

Please consult your healthcare provider before starting or changing any medication

Currently, retatrutide has not been approved by the FDA as it is still in clinical phase 3 trials

Related research context Retatrutide is part of the GLP-1/GIP/glucagon triple-receptor agonist metabolic research class

Multisite research, including research at UAB, shows that oral semaglutide is nearly as effective as the widely used injectable version for treating obesity, delivering about 13.7 percent average weight loss over 64 weeks